Update on hepatitis C virus resistance to direct-acting antiviral agents

Antiviral Research

Volumn 108, Issue 1, 2014, Pages 181-191

  Poveda, Eva ^a   Wyles, David L ^b   Mena, Álvaro ^a   Pedreira, José D ^a   Castro Iglesias, Ángeles ^a   Cachay, Edward ^b  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Direct acting antivirals; Drug resistance; Hepatitis C virus

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; INTERLEUKIN 28B; LEDIPASVIR; MERICITABINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; SOFOSBUVIR; TELAPREVIR; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL PRACTICE; CROSS RESISTANCE; DRUG TREATMENT FAILURE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; GENETICS; HEPACIVIRUS; MISSENSE MUTATION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HUMANS; MUTATION, MISSENSE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84903701056     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.05.015     Document Type: Review

References (89)

1. The AASLD/IDSA Clinical Guidance for Hepatitis C. March 21, 2014. Available from: < http://www.hcvguidance.org >.
2. N. Afdhal, K. Reddy, and D. Nelson et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection N. Engl. J. Med. 370 2014 1483 1493
3. N. Afdhal, S. Zeuzem, and P. Kwo et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N. Engl. J. Med. 2014
4. S. Ali, V. Leveque, and S. Le Pogam et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479 Antimicrob. Agents Chemother. 52 2008 4356 4369
5. T. Asselah Sofosbuvir-based interferon-free therapy for patients with HCV infection J. Hepatol 2013 Available from: < http://dx.doi.org/10.101016/j. jhep.2013.07.023 >
6. T. Asselah, and P. Marcelin Interferon free therapy with direct acting antivirals for HCV Liver Int. 33 Suppl. 1 2013 93 104
7. B. Bacon, S. Gordon, and E. Lawitz et al. Boceprevir for previously treated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1207 1217
8. A. Bae, S.C. Sun, and X. Qi et al. Susceptibility of treatment-naïve hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors Antimicrob. Agents Chemother. 54 2010 5288 5297
9. R.J. Barnard, J.A. Howe, and R.A. Ogert et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical trials Virology 444 2012 329 336
10. D. Bartels, Y. Zhou, and E. Zhang et al. Natural prevalence of HCV variants with decreased sensitivity to NS3-4A protease inhibitors in treatment-naïve subjects J. Infect. Dis. 198 2008 800 807
11. K.L. Berger, L. Lagacé, and I. Triki et al. Viral resistance in hepatitis C genotype-1 infected patients receiving the NS3 protease inhibitor faldaprevir (BI 2011335) in a phase 1b multiple rising-dose study Antimicrob. Agents Chemother. 57 2013 4928 4936
12. S. Bressanelli, L. Tomei, and F. Rey et al. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides J. Virol. 76 2002 3482 3492 (Pubitemid 34224549)
13. R. De Francesco, and A. Carfi Advances in the development of new therapeutic agents targeting NS3-4A serine protease or the NS5b RNA-dependent RNA polymerase of the hepatitis C virus Adv. Drug Deliv. Rev. 59 2007 1242 1262 (Pubitemid 350047514)
14. A. De Luca, S. Di Giambenedetto, and M. Prosperi et al. Two distinct HCV genotype 1a clades: geographical distribution and association with natural resistance mutations to HCV NS3/4A inhibitors Antivir. Ther. 18 Suppl. 1 2013 A47
15. S. De Nicola, and A. Aqhemo Second wave anti-HCV protease inhibitors. Too Little too late? Liver Int. 2014 (epub ahead of print)
16. Dore, G.J.; Lawitz, E.; Hezode, C.; et al.; 2013. Daclatasvir combined with peginterferon alfa 2a-ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 study. In: 48th Annual Meeting of the European Association for the Study of the Liver, 24-28 April 2013, Amsterdam, Belgium. (Abstract 1418).
17. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection J. Hepatol. 55 2011 245 264
18. Fabrycki, J.; Patel, D.; Yang, G.; et al.; 2012. Characterization of HCV NS3 protease variants from patients enrolled in a 28-day phase 2a trial of ACH-1625 daily dosing plus pegIFN-alpha 2a/RBV. In: 47th Annual Meeting of the European Association for the Study of the Liver, 18-22 April 2012, Barcelona, Spain. (Abstract 1182).
19. Foster, G.; et al.; 2014. Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 April, 2014, London, UK. (Abstract 066).
20. R. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob. Agents Chemother. 54 2010 3641 3650
21. R.A. Fridell, C.F. Wang, and J.H. Sun et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 54 2011 1924 1935
22. E.J. Gane et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naive HCV genotype-1 infected patients J. Hepatol 56 Suppl. S2 2012 S555 S556
23. E.J. Gane, P. Pockros, and S. Zeuzem et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-naïve HCV genotype 1-infected patients J. Hepatol. 56 2012 S555 S556
24. M. Gao Antiviral activity and resistance of HCV NS5A replication complex inhibitors Curr. Opin. Virol. 3 2013 1 7
25. M. Gao, R. Nettles, and M. Belema et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
26. D. Ge, J. Fellay, and A. Thompson et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 2009 399 401
27. E.J. Gene, C.A. Stedman, and R.H. Hyland et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N. Engl. J. Med. 368 2013 34 44
28. L. Gerber, T. Welzel, and S. Zeuzem New therapeutic strategies in HCV: polymerase inhibitors Liver Int. 33 Suppl. 1 2013 85 92
29. P. Halfon, and S. Locarnini Hepatitis C virus resistance to protease inhibitors J. Hepatol. 55 2011 192 206
30. I. Jacobson, J. McHutchison, and G. Dusheiko et al. Telaprevir for previously untreated chronic hepatitis C virus infection N. Engl. J. Med. 364 2011 2405 2416
31. Jacobson, I.; Dore, G.; Foster, G.; et al.; 2013. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-population in the QUEST-1 and 2 Phase III trials. In: 64th Annual Meeting of the American Association for the Study of Liver Disease. 1-5 November, 2013, Washington DC, USA. (Abstract 1122).
32. T.L. Kieffer, A.D. Kwong, and G.R. Picchio Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs) J. Antimicrob. Chemother. 65 2010 202 212
33. T. Kieffer, S. De Meyer, and D. Bartels et al. Hepatitis C Viral evolution in genotypes 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy clinical trials PLoS One 7 2012 e34372
34. T. Kuntzen, J. Timm, and A. Berical et al. Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
35. A.M. Lam, C. Espiritu, and S. Bansal et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus Antimicrob. Agents Chemother. 56 2012 3359 3368
36. D. Larrey, A. Lohse, and C. Trepo et al. Antiviral effect, safety, and pharmacokinetics of 5 days'oral administration of deleobuvir (BI 207127), and investigational HCV RNA polymerase inhibitor, in patients with chronic hepatitis C Antimicrob. Agents Chemother. 57 2013 4727 4735
37. E. Lawitz, M. Rodriguez-Torres, and V.K. Rustgi et al. Safety and antiviral activity of ANA598 in combination with pegylated interferon alpha 2a plus ribavirin in treatment-naïve genotype-1 chronic HCV patients Hepatology 52 2010 334A 335A
38. Lawitz, E.; Hazan, L.; Gruener, D.; et al.; 2012. GS-9669, a novel NS5B non-nucleoside thumb site II inhibitor, demonstrates potent antiviral activity, favorable safety profile and potential for once-daily. In: 47th Annual Meeting of the European Association for the Study of the Liver, 18-22 April 2012, Barcelona, Spain. (Abstract 1189).
39. Lawitz, E.; Wyles, D.; Davis, M.; et al.; 2013a. Sofosbuvir + peginterferon + ribavirin for 12 weeks achieves 90% SVR12 in genotype 1, 4, 5, or 6 HCV infected 90% SVR12 in genotype 1, 4, 5, or 6 HCV infected patients: the NEUTRINO study. In: 48th Annual Meeting of the European Association for the Study of the Liver, 24-28 April, Amsterdam, Belgium. (Abstract 1411).
40. Lawitz, E.; Poordad, F.; Brainard, D.M.; et al.; 2013b. Sofosbuvir in combination with peginterferon and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. In: 64th Annual Meeting of the American Association for the Study of Liver Disease, 1-5 November, 2013, Washington DC, USA. (Abstract LB-4).
41. E. Lawitz, F. Poordad, and P.S. Pang et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomized, phase 2 trial Lancet 383 2014 515 523
42. O. Lenz, J. Bruijne, and L. Vijgen et al. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy Gastroentorology 143 2012 1176 1178
43. O. Lenz, L. Vijgen, and J.M. Berke et al. Virologic response and characterization of HCV genotype 2-6 in patients receiving TMC435 (stydy TMC435-C202) J. Hepatol. 58 2013 445 451
44. Lenz, O.; Fevery, B.; Verbinnen, T.; et al.; 2013b. Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies. In: 64th Annual Meeting of the American Association for the Study of Liver Disease. 1-5 November, 2013, Washington DC, USA. (Abstract 1101).
45. Lenz, O.; Fevery, B.; Vijgen, L.; et al.; 2013. TMC-435 in patients infected with HCV genotype 1 who failed previous pegylated interferon/ribavirin treatment: virologic analyses of the ASPIRE trial. In: Presented at 49th Annual Meeting of the European Association for the Study of the Liver, 18-22 April 2013, Barcelona, Spain. (Abstract 1329).
46. Manns, M.; Vierling, J.M.; Bacon, B.R.; et al.; 2013. High sustained viral response at 12- and 24-week follow-up of MK-5172 with pegylated interferon alfa-2b and ribavirin in HCV genotype 1 treatment-naïve non-cirrhotic patients. In: 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013), 24-28 April, 2013, Amsterdam, Belgium. (Abstract 66).
47. Manss, M.; Pol, S.; Jacobson, I.M.; et al.; 2013. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 HALLMARK-DUAL study results. In: 49th Annual Meeting of the European Association for the Study of the Liver, 9-13 April 2013, London, UK. (Abstract O166).
48. M. Martell, J.I. Esteban, J. Quer, J. Genesca, A. Weiner, and R. Esteban et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution J. Virol. 66 1992 3225 3229
49. A.L. McCormick, L. Wang, and A. Garcia et al. Development of a panel of genotype-specific resistance assays for the detection of amino acid changes in domain 1 of hepatitis C virus (HCV) NS5A associated with drug resistance Antivir. Ther. 18 Suppl. 1 2013 A56
50. J. McHutchison, E. Lawitz, and M. Shiffman et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N. Engl. J. Med. 361 2009 580 593
51. F. Mcphee, J. Friborg, and S. Levine et al. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir Antimicrob. Agents Chemother. 56 2012 3670 3681
52. F. McPhee, D. Hernandez, and F. Yu et al. A description of virologic escape in HCV genotype 1-infected patients treated with daclatasvir (BMS-790052) in combination with ribavirin and peginterferon alfa-2a or peinterferon alfa-2b J. Hepatol. 56 2012 S473
53. McPhee, F.; Toyota, J.; Chayama, D.; et al.; 2013. Analysis of HCV resistance variants in a phase 3 trial of daclatasvir combined with asunaprevir for Japanese patients with genotype 1b infection. In: 64th Annual Meeting of the American Association for the Study of Liver Disease, 1-5 November, 2013, Washington DC, USA. (Abstract 1111).
54. A.U. Neumann, N.P. Lam, and H. Dahari et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy Science 282 1998 103 107 (Pubitemid 28471138)
55. R.A. Ogert, J.A. Howe, and J.M. Vierling et al. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial Antivir. Ther. 18 2013 387 397
56. A. Osinusi, E.G. Meissner, and Y.-J. Lee et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
57. F. Pauwels, W. Mostmans, and L. Quirymen et al. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors J. Virol. 81 2007 6909 6919 (Pubitemid 46986627)
58. J.M. Pawlotsky Treatment of chronic hepatitis C: current and future Curr. Top. Microbiol. Immunol. 369 2013 321 342
59. J.M. Pawlotsky, S. Chevaliez, and J. McHutchison The hepatitis C virus life cycle as a target for new antiviral therapies Gastroenterology 132 2007 1979 1998 (Pubitemid 46695724)
60. J.M. Pawlotsky, I. Najera, and I. Jacobson Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase Antivir. Ther. 17 2012 411 423
61. B.E. Pickett, R. Striker, and E.J. Lefkowitz Evidence for separation of HCV subtype 1a into two distinct clades J. Viral Hepat. 18 2011 608 618
62. Z. Plaza, V. Soriano, and M.M. Gonzales et al. Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients J. Antimicrob. Chemother. 66 2011 2838 2842
63. Z. Plaza, V. Soriano, and E. Vispo et al. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor Antivir. Ther. 17 2012 921 926
64. P. Pockros Nucleoside/nucleotide analogue polymerase inhibitors in development Clin. Liver Dis. 17 2013 123 128
65. P.J. Pockros, D. Jensen, and N. Tsai et al. JUMP-C: a randomized trial of mericitabine plus pegylated interferón alpha-2a/ribavirin for 24 weeks in treatment-naive HCV genotypes 1/4 patients Hepatology 58 2013 514 523
66. F. Poordad, J. McCone, and B. Bacon et al. Boceprevir for untreated chronic HCV genotype 1 infection N. Engl. J. Med. 364 2011 1195 1206
67. E. Poveda, and F. García Telaprevir resistance Enferm. Infecc. Microbiol. Clin. 31 Suppl 3 2013 26 32
68. E. Poveda, and V. Soriano Drug resistance testing in hepatitis C therapy Future Virol. 7 2012 1 13
69. E. Poveda, E. Vispo, and P. Barreiro et al. Predicted challenges using direct acting antivirals in the current HIV-HCV coinfected population in Spain Antivir. Ther. 17 2012 571 575
70. C.T. Ranjith-Kumar, and C. Cheng Kao Biochemical activities of the HCV NS5B RNA-dependent RNA polymerase S.L. Tan, Hepatitis C Viruses: Genomes and Molecular Biology 1st ed. 2006 Horizon Bioscience Norfolk 293 310
71. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
72. C. Sarrazin, H. Reesink, and S. Zeuzem et al. Treatment with telaprevir/PEG-IFN/RBV after 14 days telaprevir exposure in phase I studies: results from the phase IIIB C219 rollover study J. Hepatol. 58 2013 S369 S370
73. Sherman, K.; Sulkowski, M.; Zoulim, F.; et al.; 2011. Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis of the extend study. Hepatology 54, 485A-486A.
74. V. Soriano, A. Perelson, and F. Zoulim Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J. Antimicrob. Chemother. 62 2008 1 4 (Pubitemid 351865869)
75. V. Soriano, E. Vispo, and E. Poveda et al. Directly acting antivirals against hepatitis C virus J. Antimicrob. Chemother. 66 2011 1673 1686
76. V. Soriano, E. Vispo, and C. de Mendoza et al. Hepatitis C therapy with HCV NS5B polymerase inhibitors Expert Opin. Pharmacother. 14 2012 1161 1170
77. M. Sulkowski, D. Gardiner, and M. Rodriguez-Torres et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N. Engl. J. Med. 370 2014 211 221
78. V. Summa, S.W. Ludmerer, and J.A. McCauley et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4A protease with broad activity across genotypes and resistant variants Antimicrob. Agents Chemother. 56 2012 416 417
79. T.L. Tellinghuisen, J. Marcotrigiano, and A.E. Gorbalenya et al. The NS5A protein of hepatitis C virus is a zinc metalloprotein J. Biol. Chem. 279 2004 48576 48587 (Pubitemid 39625732)
80. X. Tong, S. Le Pogam, L. Li, K. Haines, K. Piso, V. Baronas, J.M. Yan, S.S. So, K. Klumpp, and I. Nájera In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir J. Infect. Dis. 209 2014 668 675
81. A. Treviño, C. de Mendoza, and P. Parra et al. Natural polymorphisms associated with resistance to new antivirals against hepatitis C virus (HCV) in newly diagnosed HIV/HCV-coinfected patients in Spain Antivir. Ther. 16 2011 413 416
82. P. Trimoulet, C. Belzunce, and M. Faure et al. HCV protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients HIV Med. 12 2011 506 509
83. P. Troke, M. Lewis, and P. Simpson et al. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients Antimicrob. Agents Chemother. 56 2012 1331 1339
84. J. Vermehren, and C. Sarrazin The role of resistance in HCV treatment Best Pract. Res. Clin. Gastroenterol. 26 2012 487 503
85. World Health Organization. Hepatitis C factsheet No. 164. Updated July 2013. Available from: < http://www.who.int/mediacentre/factsheets/fs164/en/ >.
86. G. Yang, Y. Zhao, and D. Patel et al. Impact of viral sequences beyond HCV NS5A domain I on viral susceptibility to NS5A inhibitors Antivir. Ther. 18 Suppl. 1 2013 A59
87. S. Zeuzem, P. Andreone, and S. Pol et al. Telaprevir for retreatment of HCV infection N. Engl. J. Med. 364 2011 2417 2428
88. S. Zeuzem, P. Buggisch, and K. Agarwal et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin or pegylated interferon plus ribavirin in hepatitis C Hepatology 55 2012 749 758
89. Zeuzem, S.; Dusheiko, G.M.; Salupere, R.; et al.; 2013. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotypes 2 or 3: the VALANCE trial. In: 64th Annual Meeting of the American Association for the Study of Liver Disease, 1-5 November, 2013, Washington DC, USA. (Abstract 1085).